Abstract: Basic fi broblast growth factor (bFGF or FGF-2), a potent tumorigenic cytokine, improves cells proliferation and angiogenesis in tumor and also plays vital roles in tumor growth, metastasis as well as prognosis. Screening and application of effective cytokines against bFGF tumorigenic activity would be helpful to oncologic therapy. Myostatin, a member of transforming growth factor β superfamily, recently showed an antitumor activity and was reported to induce HeLa cells apoptosis through mitochondrion pathway. The above data raised our assumption that expression level of endogenous bFGF gene may be suppressed by exogenous myostatin in myostatin-treated HeLa cells. To test the hypothesis, myostatin was employed to stimulate HeLa cells and expressional level of endogenous bFGF gene in HeLa cells was detected with real-time RT-PCR and ELISA. Results of the suppressed expression level of bFGF gene in Hela cells implied that myostatin may be regarded as an effective cytokine against bFGF to treat certain cancers (Fig. 3, Ref. 26). Full Text in PDF www.elis.sk.
As a mitogen and differentiation factor for neuroectoderm-or mesoderm-derived cells, basic fi broblast growth factor (bFGF or FGF-2) has been demonstrated to be a multifunctional cytokine, especially its potent tumorigenic activity (1, 2) . Background researches revealed that bFGF stimulated cells proliferation and angiogenesis in tumor and is involved in tumor growth, metastasis as well as prognosis through autocrine and paracrine manners, thus the cytokine has been regarded as a target molecule for curing cancers by concerned scientists. Based on these positive roles of bFGF on tumorigenesis, neutralizing antibodies against bFGF, employed to restrain cell growth and tumorigenesis in vivo and in vitro, have been demonstrated to inhibit the proliferation of human glioblastoma cells (3) , HeLa cells (3), melanoma cells (4) and other tumor cells expressed bFGF and membrane FGF receptors in vitro through inducing cell apoptosis. In addition, Yang et al (5) discovered that overexpression of bFGF gene stimulated proliferation of HeLa cells, whereas overexpression of antisense bFGF gene inhibited proliferation of the cancer cells.
It is well known that myostatin, a member of the transforming growth factor beta superfamily, negatively regulates skeletal muscle mass (6) . Deletion of myostatin induces muscle overgrowth while overexpression or systemic administration results in atrophy. Studies have demonstrated that myostatin inhibited the proliferation of myoblasts and satellite cells via multisignal pathways (7) (8) (9) . Overexpression of antisense myostatin enhanced differentiation of rhabdomyosarcoma RD cells (10) and suppression of myostatin induced proliferation of rhabdomyosarcoma cells through a retinoblastoma-independent pathway (11), which implied myostatin was probably involved in regulating tumorigenesis of skeletal muscle. In addition, myostatin is also concerned with other tissue-derived tumors. Bian et al (12) observed that myostatin induced apoptosis of cervical cancer HeLa cells and human lung adenocarcinoma A549 cells through mitochondrion pathway. In view of these facts, it may well be that myostatin can be selected as a drug for curing tumor in clinical application.
Previously, we described that bFGF impaired the expression of myostatin gene in murine C2C12 myoblasts (13) and extracellular signal-regulated kinase 1/2 participated in the regulatory mechanism, which improved skeletal muscle development and regeneration (14) . On the basal roles on tumor and the relationship of the two cytokines in myoblasts, we presume that there may be an interaction between bFGF and myostatin in tumor cells, and is interesting to know whether inhibition of expression of bFGF gene will be induced by myostatin in myostatin-treated tumor cells. To investigate this, in the present study, myostatin was employed to stimulate Hela cells and then mRNA and protein levels of endogenous bFGF were detected by real-time reverse transcriptionpolymerase chain reaction (RT-PCR) and indirect enzyme-linked immunosorbent assay (ELISA).
Materials and methods

Cell culture
Cervical cancer HeLa cells were cultured in Dulbecco's modifi ed Eagle's medium (DMEM) supplemented with 10 % fetal bovine serum (FBS) at 37 °C with 5 % CO 2 in a humidifi ed atmosphere.
Quantitative RT-PCR
According to our previous work (13) , total RNA was extracted and used to detect the mRNA levels of bFGF and glyceraldehydes 3-phosphate dehydrogenase (GAPDH) genes in HeLa cells, the relative abundances of the two genes were assessed by real-time RT-PCR. The quantitative RT-PCR was performed using SYBR GREEN PCR master mix on an ABI PRISM 7900 Sequence Detector System. Annealing temperatures and primer sequences of bFGF and GAPDH genes were shown as follows. For the bFGF gene, primers 5'-GACCCACACATCAAACTACAACTTC-3' and 5'-TCCATCTTCTTTCATAG CAAGGTAA-3', annealing temperature 58 °C and product size 99bp; for the GAPDH gene, primers 5'-TGATGACATCAAGAAGGTGGTGAAG-3' and 5'-TCCTTGGAGGCC ATGTAGGCCAT-3', annealing terperature 62 °C and product size 240bp, bFGF mRNA level was normalized with GAPDH mRNA level.
Detection of bFGF protein content in cell culture medium
In the light of our published paper (13), indirect ELISA was used to detect bFGF protein level in cell culture medium. The method was briefl y described as follow. A 96-well fl at-bottomed assay plate coated with monoclonal antibody against human bFGF at the concentration of 5 μg/ml was kept at 4 °C for 8h and then washed three times with PBS containing 1 % Tween-20 (PBST), 1 % skim milk powder was added into plate wells followed by incubation for another 1h at 37 °C in a humidifi ed atmosphere. Cell culture supernatant was added into washed plate and kept at 37 °C for 2 h. Plate was washed three times with PBST again, polyclonal antibody against bFGF was added into the washed wells and then incubated for 1h at 37 °C. A secondary antibody labeled with horseradish peroxidase was added into the rewashed wells and incubated for 1h at 37 °C. After washing plate, TMB was added into wells and kept for 10min in dark conditions at room temperature for color development. The optical density values were read at the wavelength of 450 nm.
Western blotting analysis
The western blotting assay procedure for β-actin protein in Hela cells was following. Cells in dishes were lysed at 4 °C in non-denaturing cell lysis buffer, the harvested lysate was denatured in protein sample buffer for 5 min in boiling water. Followed SDS-polyacrylamide gel electrophoresis (SDS-PAGE), protein was transferred to nitrocellulose membrane and then probed with antibodies. SuperSignal West Pico chemiluminesence detection system (Pierce, Rockford, USA) was employed to visualize the membrance. For western blotting analysis of bFGF protein secreted into cell culture supernatant, harvested cell culture supernatant was concentrated by nine times, denatured in protein sample buffer for 5min in boiling water and subjected to SDS-PAGE. The following process was same as the detection procedure of β-actin. Content of bFGF protein was normalized with β-actin protein.
Statistical analysis
Statistical analysis was performed using the SPSS software and Student's t-test was used to determine signifi cant differences between the groups. Signifi cance was considered at p<0.05 or p<0.01.
Results
Ground on the opposite biological roles of bFGF and myostatin on HeLa cells and our published relationship between the two growth factors in murine C2C12 myoblasts, we speculated (Figs 1 and 2) showed that myostatin obviously downregulated both mRNA level in HeLa cells (p<0.01) and protein content of bFGF, secreted by the tumor cells into supertanant (p<0.01) at the two scheduled time points. Meanwhile, it was found that the inhibition effects were in a dose-dependent manner and the minimum dose (50 ng/ml) given in this experiment signifi cantly suppressed the expression of endogenous bFGF gene in the cells (p<0.01), which suggested that in the later experiment 50 ng/ml fusion myostatin protein would be sure to be effective.
To enquire time effects of myostatin on expression of bFGF gene, we monitored bFGF levels of mRNA in cells and protein in supernatant secreted by HeLa cells stimulated with 50 ng/ml fusion myostatin. Figures 2 and 3 showed us although both mRNA and protein of bFGF were predominantly detected in the experiment, the obvious changes happened at different time point. During the scheduled treatment time, mRNA content was signifi cantly downregulated from 1h to the fi nished time (p<0.01), whereas serious downregulation (p<0.05 or p<0.01) of protein content of bFGF in culture medium was three hours later than that of mRNA.
Anyway, the results provided evidence that exogenous myostatin inhibited expression of endogenous bFGF gene in HeLa cells, the accurate molecular mechanism and whether the regulatory mechanism participated in the apoptosis process of HeLa cells induced by myostatin would be unveiled in following research work.
Discussion
Large numbers of background researches have revealed that bFGF is a tumorigenic factor worth concern, and not only stimulates cells proliferation and angiogenesis in tumor, but also plays vital roles in tumor growth, metastasis as well as prognosis. Thus, it has been chosen as a target molecule for treatment of cancers by some concerned scientists. Some bioremediation approaches aimed at bFGF have been confi rmed to be effective to suppress the proliferation of tumor cells, such as antibodies against bFGF (3, 4) , antisense bFGF gene (6, 15) , RNase-1 conjugated to bFGF (16) , inhibitor of bFGF-induced signal pathway (17-21), mimic peptide to bFGF (22) and other cytokines (23, 24) . As a negative regulative cytokine of skeletal muscle development and regeneration, myostatin is always confi ned to skeletal muscle in many studies for a long time. But recently, a novel study described that the cytokine could inhibit proliferation of some tumor cells other than skeletal muscle-derived tumor, such as cervical cancer HeLa cells and human lung adenocarcinoma A549 cells. The study also showed that myostatin-induced cell death was apoptosis and the programmed cell death was generated through mitochondrion pathway (12) . In addition, we previously reported an inhibition effect of bFGF on myostatin gene expression in murine C2C12 myoblasts (13, 14) .
From the above fi ndings, we easily suppose that during the process of myostatin-induced tumor cell apoptosis, it's on the cards that myostatin downregulates expression of endogenous bFGF gene in tumor cells. It has been reported that bFGF contains four high molecular weight protein isoforms (HMW-bFGFs) and one low molecular weight protein form (LMW-bFGF). The HMWbFGFs located in cell nucleus relate possibly to cell growth and apoptosis, while the LMW-bFGF secreted into extracellular matrix is the mainly bioactive form triggering a series of signaling transduction cascades by binding high-affi nity cell surface FGF receptors (25) . Above mentioned hypothesis was approved by our investigation in this paper. Our results provided evidence that myostatin not only impaired mRNA content of bFGF gene, but also downregulated extracellular bFGF protein secreted by HeLa cells into supernatant.
It is well documented that both bFGF and myostatin exert their opposite biological roles on cell proliferation and differentiation through intricate signal pathways respectively. Although the accurate mechanism is not completely unveiled, the cross-talk between the two cytokine-induced signal pathways is really in existence. For instance, bFGF activates extracellular signal-regulated kinase 1/2 mitogen-activated protein and phosphatidylinositol 3-kinase to regulate cyclin D1 and p27, which improve cell cycle transition from G1 to S phase (26) , whereas myostatin induces p300 degradation to silence cyclin D1 expression and then to arrest cell cycle in G1/S phase through the phosphatidylinositol 3-kinase pathway (8, 9) , so there would be an interactional relationship between the two growth factors. The conjecture was confi rmed in our previous studies, which revealed that bFGF suppressed expression of myostatin gene in murine C2C12 myoblasts and extracellular signalregulated kinase 1/2 signal pathway participated in the regulatory mechanism. In this paper, suppression of myostatin on expression of bFGF gene in HeLa cells has been discovered, but the unknown regulatory mechanism is yet to be worked out. Our results in this paper implied that myostatin may be regarded as an effective cytokine against bFGF to treat certain cancers.
